Study the Correlation of Zearalenone with Prevalence of Breast Cancer in Al-Najaf Province, Iraq

Abstract

Abstract Background: This study aimed to investigate the concentration of ZAN in female breast cancer patients compared to a control group. Objectives: The objective of this study was to determine the concentration of ZAN and its association with breast cancer in female patients treated at the National Educational Oncology Hospital in the Al-Najaf Province. Materials and Methods: A total of 40 female breast cancer patients who were treated at the National Educational Oncology Hospital in the Al-Najaf Province between April and August 2022 were included in the study. Additionally, 20 healthy females served as the control group. High-performance liquid chromatography (HPLC) was used to quantitatively diagnose the ratio of ZAN in the 40 breast cancer cases with positive results. Serum samples were collected in sterile Eppendorf tubes and analyzed using HPLC to determine the concentration of ZAN. Relevant patient information, including age ranges, was recorded in data sheets. Results: The results revealed a significant increase (P < 0.05) in ZAN concentrations among the breast cancer patients compared to the control group. The concentrations of ZAN were measured at 0.345394 and 0.220381 ng/mL, respectively, indicating higher ZAN levels in the breast cancer patient group. Conclusion: This study provides evidence of a significant association between ZAN concentration and breast cancer in female patients treated at the National Educational Oncology Hospital in the Al-Najaf Province. These findings contribute to the understanding of the role of ZAN in breast cancer development. Further research is warranted to explore the mechanisms underlying this relationship and potentially develop targeted interventions.